Twist Bioscience reported $96.1 million in Q3 2025 revenues, up 18% year-over-year, driven by 7% growth in synthetic biology products and 27% growth in next-generation sequencing. The company sold approximately 237,000 genes during the quarter. Adjusting for a prior one-time order, synbio revenue growth exceeded 20%. The firm narrowed its full-year guidance to $374-$376 million, citing strong demand across regions despite some headwinds in Asia-Pacific.